麻豆视频

North America Blood Glucose Monitoring Market Trends and Insights

Favorable Reimbursement Expansions (CMS, Private Payers)

Medicare鈥檚 2024 rule that broadened CGM coverage to non-intensive insulin users removed a historical barrier, doubling the eligible senior population to 5.3 million and driving a 47% prescription surge among Medicare Advantage members in 1H 2025. Commercial insurers mirrored the change and cut prior-authorization hurdles, enabling pharmacies to stock OTC CGMs nationwide. Accountable-care organizations are leveraging these benefits to trim emergency visits, accelerating revenue migration from SMBG to CGM and lifting overall blood glucose monitoring market momentum.

Technological Advances in Long-Wear CGM Sensors

Fourteen- and fifteen-day sensors such as FreeStyle Libre 3 and Dexcom G7 achieve mean absolute relative difference (MARD) scores below 8.5%, meeting insulin-dosing standards without finger-stick confirmation. Manufacturing gains from roll-to-roll electrode printing have trimmed unit costs by roughly 25% since 2024. Lower per-day monitoring costs make CGM price-competitive with multi-stick SMBG, stimulating hospital pilots and retail uptake across the blood glucose monitoring market.

Growing Type-2 Adoption of CGM Beyond Insulin Users

Updated ADA Standards now recommend CGM for adults who struggle to reach glycemic targets, independent of insulin intensity. Real-world data from Kaiser Permanente showed 0.8-point A1c reductions for non-insulin users versus 0.3 points with SMBG Self-insured employers have reacted by removing copays, betting that deferred insulin progression offsets program costs. These moves collectively expand the blood glucose monitoring market by attracting a previously underserved cohort.

Shift Toward Data-Driven, AI-Enabled Diabetes Platforms

Cloud analytics turn raw glucose streams into predictive insights. Dexcom Clarity鈥檚 2025 release warns users up to 60 minutes before projected hypoglycemia. Abbott鈥檚 Libre data now feeds Tandem鈥檚 Control-IQ algorithm, allowing pumps to adjust basal rates every five minutes. FDA SaMD guidance imposes validation rigor, but ecosystem value outweighs compliance costs, underpinning the long-run expansion of the blood glucose monitoring market.

High Recurring Sensor & Strip Costs for Low-Income Users

Uninsured and underinsured adults face list prices of USD 350 per month for CGM sensors and USD 60-150 for branded SMBG strips ^{[1]Diabetes Patient Advocacy Coalition, 鈥�2025 Patient Cost Survey,鈥� diabetespac.org}. Cost burden leads to test rationing, raising risks of undetected hypo- and hyperglycemia. Although makers offer discount plans, enrollment caps leave many excluded, tempering near-term blood glucose monitoring market penetration in lower-income segments.

State-By-State Medicaid Coverage Disparities

Only 10 states provide unrestricted CGM access, whereas 22 restrict coverage to intensive insulin users ^{[2]Kaiser Family Foundation, 鈥淢edicaid CGM Coverage Policies by State,鈥� kff.org}. Approval delays stretch to 90 days in Texas and Florida, depressing adoption rates among the 12 million Medicaid beneficiaries with diabetes in those jurisdictions. Fragmentation obliges suppliers to manage 50 reimbursement rules, inflating administrative overhead and dampening growth in the blood glucose monitoring market until policy harmonization materializes.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Device Type: CGM Gains While SMBG Holds Volume

CGM revenue is set to eclipse SMBG despite SMBG's 60.1% blood glucose monitoring market share in 2025. CGM鈥檚 13.76% growth rate reflects extended-wear sensors, OTC availability, and Medicare expansion. The blood glucose monitoring market size for CGM is projected to compound faster as cost-per-day falls and clinical accuracy rises ^{[3]Abbott Laboratories, 鈥淎bbott Annual Report 2025,鈥� abbott.com}. SMBG remains entrenched in hospitals where point-of-care meters integrate with electronic health records, but even here, connected meters aim to mimic continuous data flow.

A bifurcated adoption pattern is emerging: majority of newly diagnosed type 1 children start on CGM within three months, yet elderly uptake lags due to interface complexity. Vendors are responding with simplified receivers and implantable six-month sensors, moderating attrition. Combined, these dynamics sustain a healthy pipeline for both premium CGM and value-focused SMBG devices inside the broader blood glucose monitoring market.

By Applications: Diabetes Management Dominates, Wellness Monitoring Emerges

Therapeutic diabetes management applications accounted for 73.21% of the 2025 value, underpinning the largest slice of the blood glucose monitoring market share. Closed-loop pumps, telehealth reviews, and population-health dashboards intensify data utilization, supporting a 14.78% forward growth path. 

Wellness-oriented monitoring via subscription models such as Levels Health introduces CGM to fitness enthusiasts and pre-diabetics, growing awareness beyond clinical indications. Though still a modest slice of the blood glucose monitoring market size, lifestyle adoption contributes incremental sensor volume and could channel users into therapeutic pathways upon diagnosis.

By Age Group: Pediatric Surge, Adult Base

Adults maintained 73.1% share in 2025, reflecting type 2 prevalence. The pediatric segment, however, is projected to post 15.6% CAGR as school policies allow in-class monitoring and FDA labels extend to children as young as two. Manufacturers simplify insertion and enable caregiver viewing, improving adherence among minors.

Within geriatrics, CGM has limited penetration for those less than more than 75 years compared with high adoption among the 65-74 cohort. Skin fragility and smartphone literacy hurdles slow conversion, yet implantable options and simplified readers could unlock upside, sustaining incremental growth for the blood glucose monitoring market.

By Test Type: Invasive Dominates, Non-Invasive Gains Attention

Invasive modalities captured 61.65% share in 2025, but non-invasive prototypes such as Know Labs鈥� Bio-RFID are targeting FDA filings by 2026. If trials achieve sub-10% MARD, non-invasive wearables may widen the blood glucose monitoring market size by appealing to sensor-phobic users. 

Optical methods still face pigmentation and hydration interference, keeping clinical clearance elusive. Nevertheless, USD 420 million in 2025 venture funding signals investor faith in eventual breakthrough. Meanwhile, invasive CGM continues refining chemistry and extending sensor life, reinforcing incumbent strength.

By End User: Homecare Dominates, Hospitals Modernize

Homecare held 41.34% of 2025 revenue thanks to telehealth incentives and new RPM billing codes that pay clinicians USD 64 for 20 minutes of monthly CGM data interpretation. Preference for virtual endocrinology visits underpins a 15.11% growth outlook.

Hospitals remain indispensable for acute care, relying on centralized meters that meet Joint Commission standards. Pilot studies at Johns Hopkins show significant hypoglycemia reduction with inpatient CGM, suggesting future penetration once the FDA approves dosing decisions in the ward. Long-term-care and correctional facilities represent smaller but specialized segments that demand rugged, easily auditable devices, rounding out opportunities in the blood glucose monitoring market.

Geography Analysis

The United States anchors the blood glucose monitoring market with 83.1% of the 2025 value. Broad Medicare and commercial-payer coverage, combined with 37.3 million diagnosed diabetics, sustains scale advantages for suppliers. Manufacturing near-shoring is intensifying; Dexcom鈥檚 USD 150 million Arizona plant will supply U.S. and Canadian demand, reducing European shipment risk.

Canada benefits from province-funded CGM programs, yet inter-provincial policy disparities persist. Ontario and British Columbia reimburse type 2 intensive insulin users, but Quebec applies stringent A1c thresholds, delaying uptake and capping overall Canadian contribution to the blood glucose monitoring market.

Mexico is the fastest-growing geography at 14.32% CAGR through 2031, propelled by a national program that targets 500,000 CGM placements by 2028. Abbott鈥檚 Monterrey distribution hub cuts delivery lead times, while early private-insurer pilots in urban centers hint at nascent commercial demand. Despite lower per-capita spending, volume growth positions Mexico as a rising contributor to the North American blood glucose monitoring market.

Regulatory Landscape

In North America, blood glucose monitoring products sit across IVD/medical device rules (for SMBG and CGM used for diabetes management) and digital-health policies (for connected apps and general-wellness claims). In the United States, integrated continuous glucose monitoring (iCGM) systems are regulated by the FDA as Class II (special controls) under 21 CFR 862.1355, which frames expectations for clinical accuracy, performance testing, and cybersecurity/data transmission controls. The FDA has also reinforced boundaries for non-invasive wearables, including a February 2024 safety communication cautioning consumers not to use smartwatches or smart rings to measure blood glucose because such products are not authorized for that purpose.

Policy clarification around wellness positioning has become more relevant as OTC and retail channel activity expands. On January 6, 2026, the FDA issued revised guidance on general wellness products, emphasizing that products estimating physiologic parameters (including blood glucose) can only remain in the low-risk general wellness space when they avoid diagnostic/management claims and meet defined risk criteria. In Canada, Health Canada regulates glucose monitoring systems under the Medical Devices Regulations (SOR/98-282), using risk-based classification and proportional clinical evidence expectations for Class II-IV devices, along with explicit labeling requirements for in vitro diagnostic devices. Together, these requirements affect launch sequencing and bilingual labeling and IFU strategies for suppliers operating across provinces.

Market Opportunities and Future Outlook

Reimbursement expansion and retail/OTC access are widening the opportunity across type 2 cohorts and homecare workflows, shifting requirements from standalone meters to connected, service-enabled solutions. A key whitespace is interoperability across CGM, analytics, and automated insulin delivery, as manufacturers move toward device pairings that reduce lock-in friction for clinics and patients. Medtronic鈥檚 FDA 510(k) submissions in April 2025 for MiniMed 780G to function as an interoperable automated glycemic controller provide an evidence anchor for this direction, alongside broader efforts to make pump and CGM components more mix-and-match across major sensor franchises.

Product-cycle opportunity is also clustering around longer wear time, simplified onboarding, and software-delivered feature upgrades, which supports scaling in pharmacy and direct-to-consumer channels without proportionate increases in clinician workload. In February 2026, FDA 510(k) clearance for Dexcom G7 (K253737) reinforced the pace of iterative CGM upgrades under established Class II special controls. The 2024 regulatory structuring around dedicated consumer product codes for OTC CGMs also broadened the addressable market without requiring a new statutory pathway. For suppliers, the near-term commercial upside is most visible where these regulatory and channel shifts align with active payer coverage expansion, including the Medicare policy changes that added 3.5 million potential CGM users in 2024 and accelerated prescription momentum in 2025. That combination creates room for differentiated offerings such as affordability programs, data privacy compliance tooling, and clinic-facing analytics that convert continuous data into actionable care plans.